Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 13/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.43 |
| ▸ | LMNA | P02545 | 4/20 | 0.43 |
| ▸ | TSHR | P16473 | 4/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8440940 | 0.89 | KMT2A (0.48) | DPP4KMT2AGAAKCNH2LMNA | |
| SCHEMBL8268286 | 0.87 | DPP4 (0.49) | DPP4GAALMNATSHRNPSR1 | |
| SCHEMBL20041950 | 0.85 | DPP4 (0.63) | DPP4GAAKCNH2LMNATSHR | |
| SCHEMBL4487837 | 0.85 | KMT2A (0.60) | DPP4KMT2ALMNATSHRSMN1; SMN2 | |
| SCHEMBL3918944 | 0.84 | DPP4 (0.54) | DPP4KMT2AKCNH2 | |
| SCHEMBL13936184 | 0.83 | DPP4 (0.47) | DPP4KMT2AKCNH2 | |
| SCHEMBL638215 | 0.82 | DPP4 (0.55) | DPP4KCNH2SMN1; SMN2RAB9A | |
| SCHEMBL20041920 | 0.82 | DPP4 (0.66) | DPP4KMT2ALMNATSHRNPSR1 | |
| SCHEMBL4483980 | 0.81 | DPP4 (0.46) | DPP4KMT2AKCNH2 | |
| SCHEMBL4483972 | 0.81 | DPP4 (0.46) | DPP4KMT2AKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107266449-B | Process for the preparation of chiral 8- (3-amino-piperidin-1-yl) -xanthines | 勃林格殷格翰国际有限公司 | 2022-06-07 | — | — | CN | disclosed |
| EP-3539956-A1 | METHOD FOR PRODUCING CHIRAL 8- (3-AMINO-PIPERIDIN-1-YL) -XANTHINES | Boehringer Ingelheim International GmbH (DE) | 2019-09-18 | — | — | EP | disclosed |
| EP-3029040-B1 | METHOD FOR PRODUCING CHIRAL 8-(3-AMINO-PIPERIDIN-1-YL) -XANTHINES | BOEHRINGER INGELHEIM INT (DE) | 2019-04-03 | — | — | EP | disclosed |
| EP-2540724-B1 | HYDROCHLORIDES OF 1-[(3-CYANO-PYRIDIN-2-YL) METHYL]-3-METHYL-7-(2-BUTIN-1-YL)-8-[3-AMINO-PIPERIDIN-1-YL]-XANTHIN, THEIR MANUFACTURE AND USE OF SAME AS MEDICINE | BOEHRINGER INGELHEIM INT (DE) | 2017-09-06 | — | — | EP | disclosed |
| US-9751855-B2 | Process for the preparation of chiral 8-(3-aminopiperidin-1-yl)-xanthines | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2017-09-05 | — | — | US | disclosed |
| US-9751855-B2 | Process for the preparation of chiral 8-(3-aminopiperidin-1-yl)-xanthines | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2017-09-05 | — | — | US | disclosed |
| US-20170129872-A1 | PROCESS FOR THE PREPARATION OF CHIRAL 8-(3-AMINOPIPERIDIN-1-YL)-XANTHINES | BOEHRINGER INGELHEIM INT (DE) | 2017-05-11 | — | — | US | disclosed |
| US-20170129872-A1 | PROCESS FOR THE PREPARATION OF CHIRAL 8-(3-AMINOPIPERIDIN-1-YL)-XANTHINES | BOEHRINGER INGELHEIM INT (DE) | 2017-05-11 | — | — | US | disclosed |
| US-20170029402-A1 | PROCESS FOR THE PREPARATION OF CHIRAL 8-(3-AMINOPIPERIDIN-1-YL)-XANTHINES | BOEHRINGER INGELHEIM INT (DE) | 2017-02-02 | — | — | US | disclosed |
| US-20170029402-A1 | PROCESS FOR THE PREPARATION OF CHIRAL 8-(3-AMINOPIPERIDIN-1-YL)-XANTHINES | BOEHRINGER INGELHEIM INT (DE) | 2017-02-02 | — | — | US | disclosed |
| US-8106060-B2 | 8-(3-amino-piperidin-1-yl)-xanthines, their preparation, and their use as pharmaceuticals | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-01-31 | — | — | US | disclosed |
| US-8106060-B2 | 8-(3-amino-piperidin-1-yl)-xanthines, their preparation, and their use as pharmaceuticals | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-01-31 | — | — | US | disclosed |
| US-7820815-B2 | for preventing or treating disorders connected with an increased DPP-IV activity, especially of diabetes mellitus type I or type II, prediabetes, or reduction of glucose tolerance; 1-[(4-methylquinazolin-2-yl)methyl]-3-methyl-7-(2-butin-1-yl)-8-(3-(R)-aminopiperidin-1-yl)-xanthine | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-10-26 | — | — | US | disclosed |
| US-20090192314-A1 | PROCESS FOR THE PREPARATION OF CHIRAL 8-(3-AMINOPIPERIDIN-1YL)-XANTHINES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-07-30 | — | — | US | disclosed |
| US-20090137801-A1 | 8-[3-AMINO-PIPERIDIN-1-YL]-XANTHINES, THEIR PREPARATION AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-05-28 | — | — | US | disclosed |
| US-7501426-B2 | 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-03-10 | — | — | US | disclosed |
| US-7495002-B2 | 3-methyl-7-butinyl-xanthines, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-02-24 | — | — | US | disclosed |
| US-20070027168-A1 | 8-(3-AMINO-PIPERIDIN-1-YL)-XANTHINES, THEIR PREPARATION, AND THEIR USE AS PHARMACEUTICALS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-02-01 | — | — | US | disclosed |
| US-20070027168-A1 | 8-(3-AMINO-PIPERIDIN-1-YL)-XANTHINES, THEIR PREPARATION, AND THEIR USE AS PHARMACEUTICALS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-02-01 | — | — | US | disclosed |
| US-20060079541-A1 | 3-methyl-7-butinyl-xanthines, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-04-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170029402-A1 | PROCESS FOR THE PREPARATION OF CHIRAL 8-(3-AMINOPIPERIDIN-1-YL)-XANTHINES | XDH, UGT1A8, CYP2C8 | DPP4 355/4885KMT2A 1737/4885GAA 2306/4885 |
| US-20090192314-A1 | PROCESS FOR THE PREPARATION OF CHIRAL 8-(3-AMINOPIPERIDIN-1YL)-XANTHINES | UGT1A8, XDH, CYP2C8 | DPP4 324/4885KMT2A 2296/4885GAA 2608/4885 |
| US-20070027168-A1 | 8-(3-AMINO-PIPERIDIN-1-YL)-XANTHINES, THEIR PREPARATION, AND THEIR USE AS PHARMACEUTICALS | PDE8B, PDE8A, XDH | DPP4 148/4885KMT2A 2489/4885GAA 868/4885 |
| US-20090137801-A1 | 8-[3-AMINO-PIPERIDIN-1-YL]-XANTHINES, THEIR PREPARATION AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS | DPP8, DPP4, DPP7 | DPP4 2/4885KMT2A 2927/4885GAA 205/4885 |
| US-20170129872-A1 | PROCESS FOR THE PREPARATION OF CHIRAL 8-(3-AMINOPIPERIDIN-1-YL)-XANTHINES | XDH, UGT1A8, CYP2C8 | DPP4 355/4885KMT2A 1737/4885GAA 2306/4885 |
| US-20060079541-A1 | 3-methyl-7-butinyl-xanthines, the preparation thereof and their use as pharmaceutical compositions | DPP4, DPP7, DPP3 | DPP4 1/4885KMT2A 2557/4885GAA 351/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.